

PAIN AND ADDICTION

Edwin A. Salsitz, MD, DFASAM

Associate Clinical Professor of Psychiatry

Mount Sinai Beth Israel, NYC

The ASAM Board Exam Study Course in Addiction Medicine

July 2022

Financial Disclosures


Edwin A. Salsitz, MD, DFASAM

No Disclosures

“PRINCIPLES” 6th Edition

Comprehensive, Complete, Clear, References

- Chap. 37: Misuse All Controlled Medications
- Chap. 100: Basic Science and Overlap P & A
- Chap. 101: Psychological Issues
 - “If life is empty, pain will fill it up.”
- Chap. 102: Rehabilitation Modalities
- Chap. 103: Non-Opioid Pharmacotherapy
- Chap. 104: Opioid Therapy
- Chap. 105: Co-Occurring Pain and Addiction
- Chap. 106: Legal & Regulatory Issues in Opioid Prescribing



JAMA. 2015;314(20):2123



JAMA. 2016;315(17):1826


The Epidemic of Untreated Pain

Alleviating Suffering 101


Pain Relief in the USA

- 2011 IOM Report: 116 Million Americans have pain which persists for weeks to years
- \$560 - \$635 Billion per year
- Some physicians overprescribe opioids, while others refuse to prescribe
- Lack of education: Providers and Patients
 - Headache, LBP, Neck Pain, Joint Pain, Fibromyalgia


Rates of Opioid Overdose Deaths, Sales, and Treatment Admissions, United States, 1999–2010




Drug Overdose Death Rate, 2008, and Opioid Pain Reliever Sales Rate, 2010



Age-Adjusted Rates of Drug Overdose Deaths Involving Prescription Opioids, Heroin, Cocaine, Psychostimulants with Abuse Potential, and Synthetic Opioids Other than Methadone— United States, 2013–2019




Life Expectancy at Birth in the US and the Organisation for Economic Cooperation and Development, 1995-2015.



Members of the Organisation for Economic Coordination and Development include Australia, Austria, Belgium, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, Latvia, Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, the UK, and the US.

Avoiding Globalization of the Prescription Opioid Epidemic



Top 30 Opioid-Consuming Nations 2012-2014

How Did We Get Here?

“Perfect Storm”

ADDICTION RARE IN PATIENTS TREATED WITH NARCOTICS


To the Editor: Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized medical patients¹ who were monitored consecutively. Although there were 11,882 patients who received at least one narcotic preparation, there were only four cases of reasonably well documented addiction in patients who had no history of addiction. The addiction was considered major in only one instance. The drugs implicated were meperidine in two patients,² Percodan in one, and hydromorphone in one. We conclude that despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.

JANE PORTER
HERSHEL JICK, M.D.
Boston Collaborative Drug
Surveillance Program

Waltham, MA 02154 Boston University Medical Center

1. Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind Y, Slone D. Comprehensive drug surveillance. JAMA. 1970; 213:1455-60.
2. Miller RR, Jick H. Clinical effects of meperidine in hospitalized medical patients. J Clin Pharmacol. 1978; 18:180-8.

Number and Type of Citations of the 1980 Letter, According to Year.



Leung PT et al. N Engl J Med 2017;376:2194-2195.

THE NEW ENGLAND
JOURNAL of MEDICINE

- **1980→ 2017: 608 citations** : ~75% used as evidence that addiction is rare with COT and made no mention that these were hospitalized patients with few doses of opioids.
- 11 other letters from 1980 were cited on average, 11 times.

“Perfect Storm”

- 1995: Introduction of Oxycontin
- 1995: Pain is Fifth Vital Sign
- Publications indicating low risk of addiction
- Thought Leaders with Financial/Pharma Conflicts
- Patient Satisfaction Surveys: “...staff did everything they could to help you with your pain”
- Physicians successfully sued for not treating pain
- No Evidence long term Effectiveness COT → CNCP
- Physical Dependence vs Addiction

Doctor liable for not giving enough pain medicine

June 14, 2001 Posted: 12:28 AM EDT (0428 GMT)



HAYWARD, California (CNN) -- In a civil case that could have broad ramifications for how patients in pain are treated, a California jury Wednesday found a doctor liable for recklessness and abuse for not prescribing enough pain medication to a patient, who later died of cancer.

The jury in Alameda County Superior Court called on the doctor to pay the patient's family \$1.5 million dollars for pain and suffering of the patient. Under California law, however, the cap for such awards is \$250,000, and the judge will likely reduce the jury's award.

A Doctor Who Prescribed 500,000 Doses of Opioids Is Sent to Prison for 40 Years

Dr. Joel Smithers was convicted of more than 800 counts of illegally prescribing opioids, and jurors found that the drugs he prescribed caused the death of a woman.



By Adeel Hassan

Oct. 2, 2019



A Virginia doctor who prescribed more than 500,000 doses of opioids in two years was sentenced to 40 years in prison on Wednesday for leading what prosecutors called an interstate drug distribution ring.

ORIGINAL RESEARCH

Prescription Opioid Use among Adults with Mental Health Disorders in the United States

Matthew A. Davis, MPH, PhD, Lewei A. Lin, MD, Haiyin Liu, MA, and Brian D. Sites, MD, MS

Background: The extent to which adults with mental health disorders in the United States receive opioids has not been adequately reported.

Methods: We performed a cross-sectional study of a nationally representative sample of the noninstitutionalized U.S. adult population from the Medical Expenditure Panel Survey. We examined the relationship between mental health (mood and anxiety) disorders and prescription opioid use (defined as receiving at least 2 prescriptions in a calendar year).

Results: We estimate that among the 38.6 million Americans with mental health disorders, 18.7% (7.2 million of 38.6 million) use prescription opioids. Adults with mental health conditions receive 51.4% (60 million of 115 million prescriptions) of the total opioid prescriptions distributed in the United States each year. Compared with adults without mental health disorders, adults with mental health disorders were significantly more likely to use opioids (18.7% vs 5.0%; $P < .001$). In adjusted analyses, having a mental health disorder was associated with prescription opioid use overall (odds ratio, 2.08; 95% confidence interval, 1.83–2.35).


Conclusions: The 16% of Americans who have mental health disorders receive over half of all opioids prescribed in the United States. Improving pain management among this population is critical to reduce national dependency on opioids. (J Am Board Fam Med 2017;30:407–417.)



Conclusions: The 16% of Americans who have mental health disorders receive over half of all opioids prescribed in the United States. Improving pain management among this population is critical to reduce national dependency on opioids.


Adverse Selection

Prescription Opioid Trends: 1999-2010



National Vital Statistics System, 1999-2008; Automation of Reports and Consolidated Orders System of the DEA; Treatment Episode Data Set

National Drug Overdose Deaths Involving Benzodiazepines, by Opioid Involvement, Number Among All Ages, 1999-2020



*Among deaths with drug overdose as the underlying cause, the benzodiazepine category was determined by the T402.2 ICD-10 multiple cause-of-death code. Source: Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2020 on CDC WONDER Online Database, released 12/2021.

New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines

FDA: August 2016

**Table 1. The Danger of Combining Opioids
And Benzodiazepines**

FDA Warning: Risks From Concomitant Use
With Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

- Reserve concomitant prescribing of (opioid) and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate
- Limit dosages and durations to the minimum required
- Follow patients for signs and symptoms of respiratory depression and sedation

Source: US Food and Drug Administration website. Available at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518697>.

FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks

This provides updated information to the [FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning \(/Drugs/DrugSafety/ucm518473.htm\)](#) issued on August 31, 2016.

Safety Announcement


[9-20-2017] Based on our additional review, the U.S. Food and Drug Administration (FDA) is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system (CNS). The combined use of these drugs increases the risk of serious side effects; however, the harm caused by untreated opioid addiction can outweigh these risks. Careful medication management by health care professionals can reduce these risks. We are requiring this information to be added to the buprenorphine and methadone drug labels along with detailed recommendations for minimizing the use of medication-assisted treatment (MAT) drugs and benzodiazepines together.

Buprenorphine and methadone help people reduce or stop their abuse of opioids, including prescription pain medications and heroin. Methadone and buprenorphine have been shown to be effective in reducing the negative health effects and deaths associated with opioid addiction and dependency.¹ These medications are often used in combination with [counseling and behavioral therapies \(https://www.samhsa.gov/medication-assisted-treatment/treatment#counseling-behavioral-therapies\)](https://www.samhsa.gov/medication-assisted-treatment/treatment#counseling-behavioral-therapies), and patients can be treated with them indefinitely. Buprenorphine and methadone work by acting on the same parts of the brain as the opioid that the patient is addicted to. The patient taking the medication as directed generally does not feel high, and withdrawal does not occur. Buprenorphine and methadone also help reduce cravings² (see Table 1. List of Buprenorphine and Methadone MAT Drugs).

Intended/Unintended Consequences in Reaction to the Prescription Opioid Epidemic

- Prescription Drug Monitoring Programs: PDMP
- Limits on the quantity and dosage prescribed
- UDTs become standard of care
- Education of prescribers: FDA REMS course on Safe and Effective Opioid Mgt.
- CDC Guidelines
- Tamper Resistant/Abuse Deterrent Formulations
- Patients Physically Dependent on Opioids Left in the Lurch
- **HEROIN: Cheaper, Readily Accessible**
- **FENTANYL/Fentanyl Analogues**

Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin



Respondents Who Endorsed Past-Month Use of OxyContin or Heroin Before and After the Introduction of an Abuse-Deterrent Formulation (ADF). Respondents include 10 784 participants in the Survey of Key Informants' Patients (SKIP) program (mean number per half-year, 991). Data are presented in 6-month increments from January 1, 2009, through June 30, 2014, and are expressed as percentages (95% CI [error bars]), with a χ^2 test for trend significance of $P < .001$ during the study period. The ADF was released in August 2010. OxyContin is a proprietary formulation of oxycodone hydrochloride.

CDC Guideline for Prescribing Opioids for Chronic Pain—3/16

Type 1 evidence: Randomized clinical trials or overwhelming evidence from observational studies.

Type 2 evidence: Randomized clinical trials with important limitations or exceptionally strong evidence from observational studies.

Type 3 evidence: Observational studies or randomized clinical trials with notable limitations.

Type 4 evidence: Clinical experience and observations, observational studies with important limitations, or randomized clinical trials with several major limitations.

- **NonPharmacologic** and **NonOpioid** therapy is preferred (Type 3)
- Before starting opioid therapy, **establish realistic treatment goals** (Type 4)
- Before starting and periodically during opioid therapy, discuss **risks, benefits, and responsibilities** for managing therapy (Type 3)
- **Immediate Release Opioids** should be used when starting therapy (Type 4)
- When opioids are started, the **Lowest Effective Dose should be used 50/90 MME** (Type 3)
- Quantity prescribed: **Acute Pain < 3 days supply, Rarely >7 days** (Type 4)
- **Evaluate Benefit vs Harm** in patient within 1-4 weeks of starting opioids (Type 4)

CDC Guideline for Prescribing Opioids for Chronic Pain—3/16

Type 1 evidence: Randomized clinical trials or overwhelming evidence from observational studies.

Type 2 evidence: Randomized clinical trials with important limitations or exceptionally strong evidence from observational studies.

Type 3 evidence: Observational studies or randomized clinical trials with notable limitations.


Type 4 evidence: Clinical experience and observations, observational studies with important limitations, or randomized clinical trials with several major limitations.

- Before starting and during therapy, **Evaluate Risk Factors (Type 4)**
- Review patient's history of controlled substance use by using the state's automated **Prescription Drug Monitoring System (PDMP) (Type 4)**
- When prescribing opioids for chronic pain, clinicians should use **Urine Drug Screens (UDS) (Type 4)**
- Avoid prescribing opioid medications with **Benzodiazepines (Type 3)**
- Offer **Substance Use Disorder Treatment** for patients when needed **(Type 2)**

Conversion to Persistent or High-Risk Opioid Use After a New Prescription From the Emergency Department: Evidence From Washington Medicaid Beneficiaries

Zachary F. Meisel, MD, MPH*; Nicoleta Lupulescu-Mann, MS; Christina J. Charlesworth, MPH; Hyunjee Kim, PhD; Benjamin C. Sun, MD, MPP


*Corresponding Author. E-mail: zfm@wharton.upenn.edu, Twitter: [@zacharymeisel](https://twitter.com/zacharymeisel).



Frequency of persistent or high-risk opioid conversion by quantity of morphine milligram equivalents prescribed at the index ED visit

Physicians' Progress to Reverse the Nation's Opioid Epidemic


AMA Opioid Task Force 2018 Progress Report



As PDMPs improve, America's physicians and health care professionals are using state PDMPs more than ever.

Prescription drug monitoring programs (PDMPs) are databases used to help inform physicians' clinical decisions. To optimize PDMP use, the AMA advocates for PDMPs to be integrated into physicians' clinical workflow to provide data at the point of care.

Total physicians registered in PDMPs



Today, more than **1.5 million** physicians and other health care professionals are registered in state-based PDMPs. Between 2016 and 2017, more than **241,000** individuals registered.²



Physicians and other health care professionals made more than **300.4 million PDMP queries** in 2017—a **121 percent increase** from 2016 and a **389 percent increase** from 2014.³

The AMA Opioid Task Force encourages all physicians to enhance their education.

In 2017, more than
549,700
PHYSICIANS

AND OTHER HEALTH CARE PROFESSIONALS across the nation completed continuing medical education (CME) trainings and accessed other education resources offered by the AMA, state and specialty societies.


Physicians are helping to improve access to high-quality, evidence-based treatment for opioid use disorder.

There are now **more than 50,000** physicians certified to provide in-office buprenorphine for the treatment of opioid use disorder across all 50 states—a **42.2 percent increase** in the past 12 months.⁷


The AMA is encouraged that in the past year, nearly 15,000 physicians have become trained and certified to provide in-office buprenorphine.

To help ensure patients receive care, health insurance companies, Medicaid, and other payers must now remove administrative barriers, such as prior authorization for medication assisted treatment (MAT).

Opioid Overdose and Prescribing Trends



Changes in Annual Opioid Prescriptions Compared to Overdose Death Rates from Different Types of Opioids



CDC Drug Overdose: US Opioid Dispensing Rate Map [Internet]. CDC. Nov 2021

Start With Non-Pharmacologic Therapy

- Physical Therapy, Exercise
- Cold, Heat
- CBT, MI
- Meditation, Mindfulness
- Acupuncture
- Biofeedback
- Massage
- Aquatic Therapy
- Spinal Cord Stimulation (SCS)

Effective Analgesic



Next Option: Non-Opioid Pharmacotherapy

- Acetaminophen (Efficacy), NSAIDS (Adverse Effects, Cardiac, Elderly)
- Anti-Depressants: TCAs, SSRIs, SNRIs
 - Neuropathic Pain, Nociceptive Pain (e.g., Fibromyalgia), Pain + Depression
- Anti-Convulsants: Gabapentanoids, Topiramate, Carbamazepine
 - Neuropathic Pain, Nociceptive Pain, Migraine Prophylaxis
- Topicals: Lidocaine Patch, NSAIDS, Capsaicin
- “Muscle Relaxants:” Baclofen, Cyclobenzadrine, Methocarbamol, Tizanidine
 - Avoid Benzodiazepines, Carisoprodol (Schedule IV)
- Ketamine: Acute Pain (e.g., ED)
- Interventional Procedures: Epidurals, Nerve Blocks, Neuro-Modulation

Gabapentanoids: Conclusions

- Significant Misuse Among Patients with SUDs, Primarily OUD Receiving Methadone or Buprenorphine Maintenance.
- Significant Adverse Effects With Therapeutic Doses, and Increased Adverse Effects With Supra-Therapeutic Doses
- Must Adjust for Renal Function
- Full Recovery From Adverse Effects Is The Rule
- **Death Is Uncommon, But Increased In Combination With Opioids**
- Gabapentin Bioavailability ↓ With Increasing Dose
- Weak Evidence For Off Label Pain Treatment
- Should Gabapentin Be Listed On PDMPs (e.g., Ohio, NJ)
- Pregabalin Schedule 5 listed
- Add Gabapentanoids To UDT Screens

Opioid Pharmacotherapy

- Acute Pain: e.g., Post-Operative
- Limit Duration: NYS-7days
- Cancer Pain
- Palliative Care, Hospice
- End of Life Care
- **Chronic Opioid Therapy (COT) for**
 - **Chronic Non-Cancer Pain (CNCP)**
 - **Effectiveness, Safety, Adverse Effects,**
 - **IR vs. ER**

Long Term(>16wks.) COT for CNCP

Long-term Opioid Treatment of Chronic Nonmalignant Pain: Unproven Efficacy and Neglected Safety.

- “..No high-quality evidence on the efficacy of COT for CNCP.” no RCT lasting >3mos
- “Until 2003, opioid addiction associated with the treatment of CNCP was clearly a neglected topic of publication.”
- **Reported Rates of Iatrogenic OUD 3-5%**
- **Currently 30-40%**

The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop

Roger Chou, MD; Judith A. Turner, PhD; Emily B. Devine, PharmD, PhD, MBA; Ryan N. Hansen, PharmD, PhD; Sean D. Sullivan, PhD; Ian Blazina, MPH; Tracy Dana, MLS; Christina Bougatsos, MPH; and Richard A. Deyo, MD, MPH

Background: Increases in prescriptions of opioid medications for chronic pain have been accompanied by increases in opioid overdoses, abuse, and other harms and uncertainty about long-term effectiveness.

Purpose: To evaluate evidence on the effectiveness and harms of long-term (>3 months) opioid therapy for chronic pain in adults.

Data Sources: MEDLINE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, PsycINFO, and CINAHL (January 2008 through August 2014); relevant studies from a prior review; reference lists; and ClinicalTrials.gov.

Study Selection: Randomized trials and observational studies that involved adults with chronic pain who were prescribed long-term opioid therapy and that evaluated opioid therapy versus placebo, no opioid, or nonopioid therapy; different opioid dosing strategies; or risk mitigation strategies.

Data Extraction: Dual extraction and quality assessment.

Data Synthesis: No study of opioid therapy versus no opioid therapy evaluated long-term (>1 year) outcomes related to pain, function, quality of life, opioid abuse, or addiction. Good- and

fair-quality observational studies suggest that opioid therapy for chronic pain is associated with increased risk for overdose, opioid abuse, fractures, myocardial infarction, and markers of sexual dysfunction, although there are few studies for each of these outcomes; for some harms, higher doses are associated with increased risk. Evidence on the effectiveness and harms of different opioid dosing and risk mitigation strategies is limited.

Limitations: Non-English-language articles were excluded, meta-analysis could not be done, and publication bias could not be assessed. No placebo-controlled trials met inclusion criteria, evidence was lacking for many comparisons and outcomes, and observational studies were limited in their ability to address potential confounding.

Conclusion: Evidence is insufficient to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. Evidence supports a dose-dependent risk for serious harms.

Primary Funding Source: Agency for Healthcare Research and Quality.

Ann Intern Med. 2015;162:276-286. doi:10.7326/M14-2559 www.annals.org
For author affiliations, see end of text.

This article was published online first at www.annals.org on 13 January 2015.

Conclusion: Evidence is insufficient to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. Evidence supports a dose-dependent risk for serious harms.

Initiating Opioid Treatment: CNCP

- Prescribers should regard initial treatment as a **therapeutic trial**
 - May last from several weeks to several months; **start with IR Opioid**
 - Decision to proceed w/ long-term treatment should be intentional and based on careful consideration of outcomes during the trial
 - Progress toward meeting therapeutic goals
 - **Functional Improvement**
 - Presence of opioid-related adverse effects
 - Changes in underlying pain condition
 - Changes in psychiatric or medical comorbidities
 - **Identification of aberrant drug-related behavior, addiction, or diversion**

Guidelines for Opioid Rotation


- Calculate equianalgesic dose of new opioid from EDT
- Reduce equianalgesic dose by 25%-50%: **incomplete cross tolerance**
- **Methadone: EDTS Not Helpful**
 - Start Low, Go Slow
 - 2% of sales / 30% of Overdose Deaths: Pain, not OTPs
- **Opioid Induced Hyperalgesia (OIH): counterintuitive but real**
 - Differentiate from Opioid Tolerance \uparrow Dose \rightarrow \downarrow Pain or \uparrow Pain

Can You Land the Opioid Plane?



Opioid Tapering/Deprescribing Strategies

- Patient Requests/Agrees vs Patient Resists
- Alternative Treatment if Pain Still Present
- Clonidine/Lofexidine Tablets and Patches
 - alpha 2 centrally acting adrenergic agonists → ↓LC → ↓NE
- Switch to Methadone
- Switch to Buprenorphine
- Symptomatic Meds: NSAIDs, Loperamide, Benzos(short course), non-benzo sleep meds
- Patients report favorable outcomes after tapering



An E.R. Kicks the Habit of Opioids for Pain

Instead of opioids, an E.R. in New Jersey now treats many pain patients with alternatives like laughing gas, trigger-point injections and even a therapy that

By JAN HOFFMAN JUNE 10, 2016

Dr. Alexis LaPietra used a non-opioid trigger point injection to treat Fausto Arce's muscle spasm, which was so painful he couldn't turn his head. Mark Makela for The New York Times

New Opioid Limits Challenge the Most Pain-Prone



Paula Span

THE NEW OLD AGE JUNE 6, 2016



Irene Cohen, 69, may represent the future of older pain patients: less of a reliance on opioid painkillers and more of an emphasis on exercise and other nonmedicinal therapy.

Patients in Pain, and a Doctor Who Must Limit Drugs

By JAN HOFFMAN MARCH 16, 2016



For Immediate Release: 6/14/2016

GOVERNOR ANDREW M. CUOMO

GOVERNOR CUOMO AND LEGISLATIVE LEADERS ANNOUNCE AGREEMENT TO COMBAT HEROIN AND OPIOID ABUSE IN NEW YORK STATE

Comprehensive Legislative Package Limits Opioid Prescriptions from 30 to 7 Days, Requires Mandatory Prescriber Education on Pain Management to Stem the Tide of Addiction, Eliminates Burdensome Insurance Barriers to Treatment

Expands Supports for New Yorkers in Recovery, Increases Treatment Beds by 270 and Expands Program Slots for Substance Use Disorder by 2,335 in New York

FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering

FDA Drug Safety Communication

Safety Announcement

[4-9-2019] The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide.

While we continue to track this safety concern as part of our ongoing monitoring of risks associated with opioid pain medicines, we are requiring changes to the prescribing information for these medicines that are intended for use in the outpatient setting. These changes will provide expanded guidance to health care professionals on how to safely decrease the dose in patients who are physically dependent on opioid pain medicines when the dose is to be decreased or the medicine is to be discontinued.

Rapid discontinuation can result in uncontrolled pain or withdrawal symptoms. In turn, these symptoms can lead patients to seek other sources of opioid pain medicines, which may be confused with drug-seeking for abuse. Patients may attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.


Opioids ([/drugs/information-drug-class/opioid-medications](#)) are a class of powerful prescription medicines that are used to manage pain when other treatments and medicines cannot be taken or are not able to provide enough pain relief. They have serious risks, including abuse, addiction, overdose, and death. Examples of common opioids include codeine, fentanyl, hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone.

Health care professionals should not abruptly discontinue opioids in a patient who is physically dependent. When you and your patient have agreed to taper the dose of opioid analgesic, consider a variety of factors, including the dose of the drug, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. No standard opioid tapering schedule exists that is suitable for all patients. Create a patient-specific plan to gradually taper the dose of the opioid and ensure ongoing

JAMA | Original Investigation

Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids

Alicia Agnoli, MD, MPH, MHS; Guibo Xing, PhD; Daniel J. Tancredi, PhD; Elizabeth Magnan, MD, PhD; Anthony Jerant, MD; Joshua J. Fenton, MD, MPH




CONCLUSIONS: Among patients prescribed stable, long-term, higher-dose opioid therapy, tapering events were significantly associated with increased risk of overdose and mental health crisis

HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics


Oct. 2019


- The CDC Guideline for Prescribing Opioids for Chronic Pain **does not recommend opioid discontinuation when benefits of opioids outweigh risks.**
- Avoid misinterpreting cautionary dosage thresholds. Guideline recommends avoiding or carefully justifying increasing dosages **above 90 MME/day, it does not recommend abruptly reducing opioids from higher dosages.**
- **Avoid dismissing patients from care.**

Urine Toxicology Results in Chronic Pain Patients on Opioid Therapy



Cannabis/Cannabinoids





- In adults with chemotherapy induced nausea and vomiting, oral cannabinoids are effective antiemetics.
- In adults with chronic pain, patients who were treated with cannabis or cannabinoids are more likely to experience a clinically significant reduction in pain symptoms
- In adults with multiple sclerosis (MS) related spasticity, short-term use of oral cannabinoids improves patient-reported spasticity symptoms.
- For these conditions the effects of cannabinoids are modest; for all other conditions evaluated there is inadequate information to assess their effects.


Opioid Use Disorder: Conflicting reports. No RCTs
Controversies About Listing as Eligible Disorder for Medicinal Cannabis by Some States

Prescription Drug Monitoring Programs: PDMPs

- All states are operational
- Some states mandatory at time of Rx, e.g., N.Y.
- Some state PDMPs include bordering and other states
- OTPs are exempt: both Methadone and Buprenorphine
- OBOT Buprenorphine included in PDMPs
- ↓ Doctor shopping and Rx opioid prescribed since 2010
- Evidence of ↓ OD deaths
- Unintentional consequences: ↑Heroin, ↑Pain, Abrupt Rx Cessation

From: **Prescription Opioid Analgesics Commonly Unused After Surgery: A Systematic Review**


JAMA Surg. Published online August 02, 2017.



Opioid Rx Disposal

- DEA Take Back Programs
- Some Pharmacies, Some Police Stations
- Mix with cat litter/coffee grounds, then seal in plastic bag and throw out in trash
- Flush down toilet: environmental issues
 - Fentanyl Patch: Flush only
- DO NOT throw out in trash in Rx bottle


Complex Intersection



Pain and Addiction: Definitions

- “Pain is viewed as a biopsychosocial phenomenon that includes **sensory, emotional, cognitive, developmental, behavioral, spiritual and cultural components.**”
(IASP website)
- Addiction is a treatable, chronic medical disease involving **complex interactions among brain circuits, genetics, the environment, and an individual’s life experiences.**
People with addiction use substances or engage in behaviors that become compulsive and often continue despite harmful consequences.

Pain and Addiction




Pain and Addiction

Limited (e.g., UDT) Objective Measurements



Opioid Sites of Action in the Brain



“Exaggerated Response”

What Did It Feel Like The First Few Times?

- “All my problems disappeared.”
- “Felt like I was under a warm blanket.”
- “Thought this is how normal people feel.”
- “Forgot about all the abuse.”
- “Felt like the world was at peace.”
- “Totally relaxed.” “Not shy.”
- “Looking at a beautiful sunset.”
- “I was energized!”
- *Liking opioids: this is a vulnerability.*

Treating Pain in the Addicted Patient

- “Pain patients with a coexisting SUD are among the most challenging patients in medicine.”
- Universal Precautions
- “Real Pain” may make opioids less rewarding/euphorogenic
- Addicted Patients Have Pain: Trauma, Lower Thresholds, Medical
- Screening Tests: ORT, SOAPP, others
- **Untreated Pain is a trigger for relapse**
- **Address both pain and addiction**
- **Significant other to secure and dispense opioid meds**
- Psychiatric Co-morbidity
- Active Addiction recovery program
- UDS, pill counts, agreements, etc.
- **Multidisciplinary Pain Program**

Buprenorphine Formulations: FDA Approved for Pain not OUD

- Buprenex® Parenteral (IV, IM)
 - Butrans® Transdermal (7 Day)
 - Belbuca® Buccal Film (75—900mcg q12h)
-
- Approved for pain but NOT OUDs
 - Can **NOT** be used **OFF LABEL** for OUDs: Violates DATA 2000

Original Investigation | Substance Use and Addiction

Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain


A Systematic Review

Victoria D. Powell, MD; Jack M. Rosenberg, MD; Avani Yaganti, BS; Claire Garpestad, MD; Pooja Lagisetty, MD, MSc; Carol Shannon, MPH; Maria J. Silveira, MD, MA, F

CONCLUSIONS AND RELEVANCE: In this systematic review, buprenorphine was associated with reduced chronic pain intensity without precipitating opioid withdrawal in individuals with chronic pain who were receiving LTOT. Future studies are necessary to ascertain the ideal starting dose, formulation, and administration frequency of buprenorphine as well as the best approach to buprenorphine rotation.

MEANING: These findings suggest that buprenorphine rotation may be a viable option for mitigating the harms of long-term opioid therapy in individuals with chronic pain who were receiving unsafe opioid analgesic regimens; further studies are needed to examine the best way to accomplish buprenorphine rotation.

Pain and Addiction




Definitions:


Complex Physical Dependence

“Dependence on opioid pain treatment is not, as we once believed, easily reversible; it is a complex physical and psychological state that may require therapy similar to addiction treatment, consisting of structure, monitoring, and counseling, and possibly continued prescription of opioid agonists. Whether or not it is called addiction, **complex persistent prescription opioid dependence** is a serious consequence of long-term pain treatment that requires consideration when deciding whether to embark on long term opioid pain therapy as well as during the course of such therapy.

Pain and Addiction




Pain and Addiction



Evolution Of Opioid Prescribing

Opioid Phobia

Opioid Philia



Opioid Cautious
Multidimensional Pain Treatment



**Baby Boomers
OK, BOOMERS!**

Pain Quotes

- “To have great pain is to have certainty. To hear that another person has pain is to have doubt.” “Seeing Pain,” Nicola Twilley (2018)
- “Physical Pain does not simply resist language, but actively destroys it.” -“The Body in Pain” by Elaine Scarry (1985)
- “Morphine is God’s own medicine” Sir William Osler
- We can’t live without opioids; we have to learn to live with them.

Good luck on the exam and in your careers!



Submit Your Feedback on this Session!



- ✓ Scan QR code or visit bit.ly/SESSIONEVAL
- ✓ Choose the session you are reviewing
- ✓ Provide your feedback

Up Next: *Patient Interventions* – Carla B. Marienfeld, MD, DFAPA, FASAM